Rejuvenate Bio logo — Targeting the core drivers of chronic age-related diseases t...

Rejuvenate Bio

Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans

Founded 2019 15 employees Grant Total: $18.58M Biotechnology, Health Care +1

General Information

Company Name Rejuvenate Bio
Founded Year 2019
Founders / Decision Makers
Team member
Employees 15
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Grant
Social

Get notified when Rejuvenate Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Rejuvenate Bio

Rejuvenate Bio is a biotechnology startup founded in 2017, aiming to combat chronic age-related diseases. The company's focus is on leveraging gene expression and epigenetic reprogramming to reverse pre-existing conditions such as heart disease, metabolic disease, and kidney failure in humans. With its slogan "Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans," Rejuvenate Bio has garnered attention in the health care industry. In April 27, 2021, the company secured a significant $14.58M in a Venture Round investment. Despite the absence of specific headquarters information, the recent investment highlights investor confidence in the potential of Rejuvenate Bio's innovative approach. This substantial funding could signify a pivotal point for the company's trajectory, as it continues to make strides in transforming the landscape of age-related disease treatment.

Taxonomy: age-related diseases, gene expression, epigenetic reprogramming, chronic diseases, reversing pre-existing conditions, heart disease, metabolic disease, kidney failure, gene therapy, medical research, anti-aging, precision medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Jul 2024
Series A •••••• 5
Investor Investor Investor
•••• ••••
12 Apr 2021
Seed Round •••••• 3
Investor Investor Investor
01 Jun 2018

Rejuvenate Bio Alternatives & Competitors

Rejuvenate Bio vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Rejuvenate Bio vs

Leveraging genetics to treat neurological diseases

IPO
163 employees
Biotechnology, Health Care
Rejuvenate Bio vs
Spur Therapeutics
Spur Therapeutics United Kingdom

Toward the next generation of gene therapy.

Post Ipo Equity
122 employees
Biopharma, Biotechnology

FAQ About Rejuvenate Bio

Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans
Rejuvenate Bio was founded in 2019.
Rejuvenate Bio operates in the following industries: Biotechnology, Health Care, Life Sciences.
Rejuvenate Bio has approximately 15 employees.
Rejuvenate Bio has completed 3 funding rounds, raising a total of $18.58M. The latest funding stage is Grant.
Top alternatives and competitors to Rejuvenate Bio include Locanabio, Inc., Voyager Therapeutics, Inc., Spur Therapeutics, Aspa Therapeutics, Anacalypsis Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rejuvenate Bio and Locanabio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Rejuvenate Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy